The researchers found that R-CHOP combined with targeted agents (R-CHOP-X) based on the 6 genetic subtypes improved the CR rate, PFS and OS in patients with DLBCL in the GUIDANCE-01 trial. The gene discussed is DDIT3; the disease is diffuse large B-cell lymphoma.